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ABSTRACT: Elevation of reactive oxygen species (ROS)
levels has been observed in many cancer cells relative to
nontransformed cells, and recent reports have suggested that
small-molecule enhancers of ROS may selectively kill cancer
cells in various in vitro and in vivo models. We used a high-
throughput screening approach to identify several hundred
small-molecule enhancers of ROS in a human osteosarcoma
cell line. A minority of these compounds diminished the
viability of cancer cell lines, indicating that ROS elevation by small molecules is insuﬃcient to induce death of cancer cell lines.
Three chemical probes (BRD5459, BRD56491, BRD9092) are highlighted that most strongly elevate markers of oxidative stress
without causing cell death and may be of use in a variety of cellular settings. For example, combining nontoxic ROS-enhancing
probes with nontoxic doses of L-buthionine sulfoximine, an inhibitor of glutathione synthesis previously studied in cancer
patients, led to potent cell death in more than 20 cases, suggesting that even nontoxic ROS-enhancing treatments may warrant
exploration in combination strategies. Additionally, a few ROS-enhancing compounds that contain sites of electrophilicity,
including piperlongumine, show selective toxicity for transformed cells over nontransformed cells in an engineered cell-line
model of tumorigenesis. These studies suggest that cancer cell lines are more resilient to chemically induced increases in ROS
levels than previously thought and highlight electrophilicity as a property that may be more closely associated with cancer-
selective cell death than ROS elevation.
R
eactive oxygen species (ROS) are a common byproduct of
cellular metabolism and are used by cells for signal
transduction and as defense agents against pathogens.
1−3
Although certain species, including nitric oxide and hydrogen
peroxide, are increasingly thought to play important roles in
signaling and regulation of protein function, other highly
reactive species can damage cellular nucleic acids, proteins, and
lipids. As a result, various mechanisms have evolved to limit
undesired cellular damage and maintain redox homeostasis.
Superoxide radical, which can be generated by NADPH
oxidases and other enzymes or by leakage of one electron
from the electron transport chain to molecular oxygen, is
processed by superoxide dismutases to provide hydrogen
peroxide and molecular oxygen (Figure 1A). Metalloenzymes
(e.g., catalase) and enzymes that harness glutathione as a
nucleophilic cofactor (e.g., glutathione peroxidase, glutathione
S-transferase) reduce hydrogen peroxide and related cellular
peroxides. Proper detoxiﬁcation of superoxide and hydrogen
peroxide is critical to prevent the formation of even more
damaging species, including peroxynitrite (by recombination of
superoxide with nitric oxide) and hydroxyl radical (by Fenton-
type cleavage of peroxides). During periods of oxidative stress,
several transcriptional programs, including the transcription
factor NRF2, can be activated to re-establish redox homeostasis
by upregulating genes bearing antioxidant response-element
promoters.
4
A role for chronic oxidative stress has been proposed in the
etiology of various diseases, including diabetes,
5,6 cardiovascular
disease,
7 and neurodegenerative diseases.
8,9 Accumulated
cellular damage initiated by ROS has also been proposed to
play a central role in the processes of aging
10,11 and
tumorigenesis.
12 More recently, insights from cancer biology
have suggested that increasing ROS levels may be a strategy for
selectively targeting cancer cells while sparing nontransformed
cells.
1,12−14 Many cancer cells have elevated basal levels of ROS
relative to nontransformed cells,
15 often as a direct result of the
activity of speciﬁc oncogenes.
16 Although this chronic oxidative
stress can enhance proliferation, migration, and other cancer
phenotypes, it may also leave some cancer cells vulnerable to
chemical agents that further elevate ROS to levels that induce
cell death.
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in vitro or in vivo models of cancer.
To explore the generality of these observations of selective
killing of cancer cells, we used a high-throughput screening
approach to identify a set of small molecules that enhance ROS
levels in a cancer cell line. Surprisingly, only a minority of ROS-
enhancing compounds lowered the viability of a panel of cancer
cell lines, demonstrating that increasing ROS levels is
frequently insuﬃcient to initiate cell death. However, cells
treated with nontoxic ROS-enhancing small molecules
appeared dependent on glutathione synthesis for survival, as
co-treatment with nontoxic doses of glutathione synthesis
inhibitor L-buthionine sulfoximine (BSO) led to potent cell
death. Selective killing of cancer cells, a property of several
known ROS-enhancing small molecules, was modest and
limited to several electrophilic small molecules. The divergent
cellular outcomes observed for small-molecule enhancers of
ROS suggest that cancer cells may be vulnerable to certain
speciﬁc ROS-elevating treatments, in particular electrophilic
small molecules, while distinctly resistant to others.
■ RESULTS AND DISCUSSION
High-Throughput Screening and Evaluation of Cel-
lular Viability. To identify novel small-molecule enhancers of
ROS levels, we adapted a high-throughput assay for ROS levels
in myotubes
23 for use in the human osteosarcoma cell line
U2OS (Figure 1B,C). To detect ROS we used CM-H2DCF-
DA, a cell-permeable, nonﬂuorescent compound that is
oxidized by hydroxyl radical, peroxynitrite, and other reactive
oxygen species (sometimes with transition metal ion catalysts)
to a ﬂuorescein derivative. Though it does not distinguish
between multiple species, CM-H2DCF-DA remains a leading
approach to measuring highly reactive species that may be most
likely to initiate cancer cell death. Piperlongumine, a naturally
occurring small molecule previously demonstrated to enhance
ROS levels in U2OS cells,
20 served as positive control.
Typically automated ﬂuorescence microscopy was used as the
detection method due to its optimal sensitivity (Figure 1B,C).
However, during high-throughput screening, a ﬂuorescence
plate reader (FLiPR, Molecular Devices) was used to enhance
assay throughput.
Figure 1. Identiﬁcation of small-molecule enhancers of ROS and evaluation of toxicity in cancer cell lines. (A) Common pathways for the generation
and metabolism of ROS. (B) U2OS cells were treated with either DMSO or 20 μM piperlongumine (PL) for 1 h, and ROS were measured using
CM-H2DCF-DA and automated ﬂuorescence microscopy. (C) Quantiﬁcation of ﬂuorescence levels following PL treatment. Mean and standard
deviation from a representative experiment are shown. (D) Summary of high-throughput screening results. Blue, negative control (DMSO); yellow,
test compounds; red, “hit” compounds (903); positive control (PL), not shown. Each assay plate was normalized to DMSO = 0, PL = 100.
Compounds scoring >75 in both replicates were considered “hits”. (E) Occurrence of toxicity (>50% reduction in ATP at ≥20 μM after 48-h
treatment) in U2OS and EJ cell lines.
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products, bioactive compounds, commercial compounds, and
products of diversity-oriented synthesis, to identify enhancers
of ROS in U2OS cells. To minimize identiﬁcation of
compounds for which ROS elevation might be a result of
ongoing cell death, ROS was detected 1 h after compound
treatment. We identiﬁed 903 compounds that increased ROS
levels to 75% of positive control levels in both assay replicates
(Figure 1D). Many compounds outperformed the positive
control, including 38 compounds that elevated ROS to levels
Figure 2. ROS-enhancing, nontoxic compounds. (A) Elevation of ROS for the indicated concentrations of each compound after 1-h treatment in
three cell lines. (B) ATP levels after 48-h treatment in the same cell line panel. All data are expressed as mean ± SD, n =3 .
Figure 3. Cellular eﬀects of ROS-enhancing, nontoxic compounds. (A) Total cellular glutathione after treatment with the indicated compounds
(BRD9092, 23.2 μM; BRD56491, 35 μM; BRD5459, 11.7 μM) was measured in EJ and HeLa cells. (B) BRD9092 and BRD5459, but not
BRD56491, elevate antioxidant response element (ARE) promoter transcription in a luciferase-based reporter-gene assay in IMR-32 cells. Data are
expressed as mean ± SD, n = 3 (ARE reporter assay, n = 4). (C−E) Three ROS-enhancing nontoxic compounds were tested for viability in the
presence of a nontoxic dose (5 μM) of BSO (a glutathione synthesis inhibitor), 200 μM vitamin E, or 5 mM N-acetyl cysteine (NAC) in EJ cells.
ATP values were calculated relative to control wells lacking the indicated BRD compound but containing BSO and antioxidant when applicable. All
treatments were nontoxic individually (Supporting Figure 4). (F) Pairing of BRD5459 (2.9 μM) or BRD9092 (11.6 μM) with BSO (5 μM) leads to
enhanced depletion of glutathione. All data are expressed as mean ± SD, n =3 .
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compounds in dose using automated ﬂuorescence microscopy
conﬁrmed 2-fold ROS enhancement for 558 compounds (1.4%
conﬁrmed hit rate) and also identiﬁed 14 autoﬂuorescent
compounds that were excluded from further analysis.
Previous reports have suggested that cancer cells may be
particularly sensitive to ROS-modulating small mole-
cules.
1,12,13,14,17 To explore this concept more generally, we
measured the sensitivity of cancer cell lines to the conﬁrmed
ROS-enhancing small molecules arising from our screen, using
cellular ATP levels to assess the eﬀect of compounds on cell
growth and viability. In U2OS cells, only 72 compounds
reduced ATP levels more than 50% at ≥20 μM after a 48-h
treatment (Figure 1E). As a larger impact on growth and
viability was expected, a second cell line (EJ) was also tested.
Similar to U2OS, only 48 compounds diminished viability at
≥20 μM. A total of 90 compounds were able to decrease ATP
by at least 50% in one or both cell lines, less than 20% of
conﬁrmed ROS-enhancing compounds. Even for the 17
compounds that enhanced ROS more than 6-fold, only six
lowered the viability of U2OS cells. Elevation of ROS to levels
attainable with small molecules may be insuﬃcient to initiate
cancer-cell death.
Further Evaluation of Nontoxic Screening Hits. Since
ROS-enhancing small molecules unexpectedly had minimal
eﬀects on the growth and viability of cancer cell lines, we
prioritized 80 nontoxic screening hits that strongly enhanced
ROS levels in U2OS for deeper characterization in cellular
viability and oxidative stress assays. In three additional cancer
cell lines, compound treatment elevated ROS levels without
apparent loss of viability (Figure 2, Supporting Figure 1).
Additionally, although ROS levels were often maximal at our
standard 1-h measurement, ROS levels were still greatly
elevated after 8- and 24-h treatment in many cases (Supporting
Figure 2A). Likewise, little eﬀect on growth and viability for
these compounds was observed even after 5 days of treatment
(Supporting Figure 2B). These data suggest that the persistence
of cell viability in the face of elevated ROS levels was not simply
due to choice of cell line or treatment length.
To provide additional evidence that ROS-enhancing small
molecules identiﬁed using CM-H2DCF-DA were indeed
causing increased levels of functional ROS in cells, we measured
their eﬀects on additional markers of cellular oxidative stress.
Treatment with these nontoxic, ROS-enhancing compounds
resulted in varying levels of decrease in total cellular glutathione
(Figure 3A). We also used a reporter-gene assay measuring
transcription from an antioxidant response element (ARE)-
containing promoter in IMR-32 cells
24 as a surrogate measure
for the activity of the redox-sensitive transcription factor NRF2.
Although some nontoxic ROS-enhancing compounds had little
to no eﬀect on ARE transcription, others led to strong
activation of an ARE promoter (BRD9092, Figure 3B). These
studies suggest that elevation of oxidative stress by small
molecules need not lead to cancer-cell death and highlight
several speciﬁc chemical probes that most strongly and
generally elevate ROS levels and other markers of oxidative
stress without loss of cellular viability. Such compounds may
elevate speciﬁc ROS that are less eﬀective at inducing cell death
or may induce oxidative stress in subcellular compartments that
are less susceptible to lethal damage. Alternatively, the elevated
ROS levels resulting from compound treatment may still be
below a threshold required to initiate cell death.
Although many ROS-enhancing small molecules do not
aﬀect cancer cell growth and viability as single agents, we
hypothesized that co-treatment with a second inducer of
oxidative stress might overcome the observed insensitivity. To
test this hypothesis, we co-treated cells with nontoxic ROS-
elevating compounds and a nontoxic dose of L-buthionine
sulfoximine (BSO), an inhibitor of glutathione biosynthesis.
Strikingly, for more than 20 nontoxic ROS-enhancing
compounds, co-treatment with 5 μM BSO in EJ cells led to
potent cell death (Figure 3C−E, Supporting Figure 3). Co-
treatment of many nontoxic ROS-enhancing compounds with
BSO did not lead to cell death, highlighting the mechanism-
dependent nature of the observed eﬀect. The loss of viability
caused by the combination of ROS-enhancing compounds and
BSO could be prevented by the chemically unrelated
antioxidants NAC and vitamin E (Figure 3C−E, Supporting
Figure 4), implicating ROS elevation in the observed cell death.
Enhanced potency for depletion of total cellular glutathione
was also observed for several ROS-enhancing compounds when
paired with BSO (Figure 3F). The ability to synthesize
glutathione may become a dependency of cells treated with
some chemical agents that give rise to a more oxidizing cellular
environment.
In two additional cancer cell lines (U2OS and H1703),
distinct sets of ROS-enhancing compounds showed highly
potent sensitization when paired with nontoxic doses of BSO
(Supporting Figure 5A,B). BRD5459 decreased viability in both
EJ and H1703 cells when paired with BSO, while PL-DHN, a
piperlongumine analogue previously shown to elevate ROS
with little eﬀect on cell viability,
25 was more potent in the
presence of BSO in all three cell lines (Supporting Figure 5C).
The genetic and physiological responses underlying the
observed cell line-dependence remain to be elucidated. Cellular
metabolism, in particular pathways that generate NADPH, a
key cofactor in many ROS-quenching processes, may play a
role in shaping cellular redox state and responses to our probe
compounds in this and other assays.
Finally, ROS-enhancing nontoxic compounds were also able
to enhance the potency of two chemotherapeutic agents
previously shown to enhance ROS levels, vinblastine and
etoposide (Supporting Figure 6).
26,27 Combining chemical
probes that induce oxidative stress may be a useful strategy to
enhance ROS-mediated cell death, even when each agent lacks
toxicity individually.
Further Evaluation of Toxic Screening Hits. In addition
to the many compounds that elevate ROS levels without
aﬀecting cancer cell growth and viability, we also identiﬁed 90
small molecules that did lower ATP levels in either EJ or U2OS
cells. Many small molecules previously shown to elevate ROS
levels and cause cancer cell death contain electrophilic centers,
including PEITC, parthenolide, and piperlongumine. Screening
hits bearing electrophilic centers (deﬁned as α,β-unsaturated
carbonyl or sulfonyl, α-halo-carbonyl, thiophenyl ester, or 2-
chloro-pyridine and related heteroaromatic groups) were
substantially more likely to cause diminished growth and
viability in our cell line panel than compounds lacking these
functional groups (17 of 41 electrophilic compounds; 73 of 527
nonelectrophilic compounds).
To assess the contribution of elevated ROS levels to the cell
death observed for our screening hits, we determined whether
the cell death caused by these compounds could be rescued
using a panel of 6 chemically diverse antioxidants. Although the
precise reactive species quenched by these antioxidants (and
ACS Chemical Biology Articles
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elevated ROS levels in cancer-cell death has previously been
inferred based on the ability of antioxidant molecules to prevent
toxicity when co-treated with ROS-enhancing stimuli.
20−22
Although these antioxidants reduced basal ROS levels as
measured by CM-H2DCF-DA by up to 45% (Supporting
Figure 7A), the viability of only a minority of toxic screening
hits was successfully rescued by our antioxidant panel, with
rescue deﬁned as >30% increase in ATP levels at any dose
following antioxidant co-treatment (Figure 4A, Supporting
Table 1). Glutathione and N-acetyl cysteine were most eﬀective
at preventing loss of viability. These two thiol-based
antioxidants rescued cell death caused by a largely overlapping
set of small molecules, most of which contain electrophilic
centers. As these antioxidants can react with and inactivate
electrophilic compounds prior to entry into cells,
28 and as other
antioxidants were generally unable to prevent cell death
mediated by electrophilic small molecules such as piperlongu-
mine (Supporting Table 1), substantial caution is warranted in
interpreting rescue of electrophilic compounds by thiol
antioxidants. Vitamin E rescued a smaller, orthogonal set of
compounds. A subset of compounds for which NAC or vitamin
E co-treatment rescued viability was also assessed for
antioxidant-mediated rescue of ROS levels. In most cases, co-
treatment with the antioxidant that prevented cell death also
mitigated compound-induced ROS increases (Supporting
Figure 7B). However, the general inability of antioxidants to
prevent cell death for most toxic screening hits suggests that
compound-induced ROS elevation may frequently be a
symptom of, or mechanistically unrelated to, cell death.
Evaluation in Isogenic Models of Tumorigenesis. A
desirable feature of some ROS-enhancing compounds is
selective induction of cell death in cancer cells but not
nontransformed cells.
1,12,13 We next assessed our collection of
toxic ROS-enhancing screening hits for diﬀerential eﬀects on
growth and viability in engineered, isogenic models of
tumorigenesis. Such models rely on the serial transfection of
human primary cells with deﬁned genetic factors that promote
immortalization, and ultimately full transformation, to cell types
capable of initiating cancers in animal models. These
engineered cell lines provide a controlled setting for high-
throughput comparisons of immortalized versus transformed
cells. We began by comparing human foreskin ﬁbroblasts
immortalized by addition of the protein subunit of telomerase
(BJhTERT) with a derivative transformed by the addition of
SV40 early region and activated HRas (BJELR).
29 Several ROS-
enhancing small molecules with electrophilic functionalities,
including the putative thioredoxin inhibitor PX-12 and
piperlongumine and its synthetic derivatives,
25 showed modest
selectivity in this viability assay (Figure 4B−E, Supporting
Figure 8A−C). Although previously we have identiﬁed distinct
cellular eﬀects for electrophilic small molecules containing one
or more electrophilic centers,
25 in this assay small molecules
bearing one (PX-12), two (PL, PL-cPr), or more (PL-TRI)
electrophilic centers showed similar magnitudes of selectivity.
In contrast, one small molecule generated by diversity-oriented
synthesis showed notable selectivity for immortalized BJhTERT
cells over the transformed BJELR derivative (Supporting Figure
8D,E).
Two additional isogenic models were analyzed that derive
from distinct human primary cells (small airway epithelial cells,
mammary epithelial cells) but use the same genetic factors to
create immortalized (SALE, HMEL) and ultimately trans-
formed (SALER, HMELR) cell lines.
30,31 Unlike the
BJhTERT/BJELR model, no ROS-elevating screening hits
showed signiﬁcant selective cell death in these cell line pairs
(data not shown). Together, these studies suggest that cancer-
selective killing is an uncommon feature of ROS-enhancing
small molecules and is most likely to be observed for those that
contain electrophilic centers.
By assembling an apparently unbiased collection of small
molecules that increase ROS levels in cancer cells, we have
been able to assess systematically the eﬀects of small-molecule
induced ROS elevation on cell viability and other cellular
processes. We provide evidence that the majority of these ROS-
enhancing compounds are unable to induce cancer-cell death as
single agents. However, such compounds frequently cause
additional markers of oxidative stress, and more than 20 caused
Figure 4. ROS-enhancing compounds show varying selectivity in isogenic models of tumorigenesis. (A) Prevention of compound-induced toxicity
using antioxidants. We deﬁned “rescue” as >30% increase in ATP levels at any compound dose following antioxidant co-treatment. No prevention of
toxicity was observed using ascorbic acid, uric acid, or β-carotene (not shown). (B−E) Measurement of ATP levels in BJhTERT and BJELR after 48-
h treatment with PX-12 (B), piperlongumine (C), and two synthetic piperlongumine analogues including a piperlongumine trimer (D, E). All data
are expressed as mean ± SD, n =3 .
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glutathione biosynthesis inhibitor BSO (Figure 5). Three such
probe compounds (BRD5459, BRD56491, and BRD9092) are
highlighted that strongly and generally elevate oxidative stress
without impacting cell viability until co-treated with BSO.
Together with PL-H2 and PL-DHN, piperlongumine analogues
previously noted to elevate ROS with minimal loss of cell
viability,
25 these probes form a novel class of nontoxic ROS-
enhancing agents that may be of use in a variety of settings in
which creating a more oxidizing cell state is desirable.
Additionally, analysis of toxic ROS-enhancing screening hits
in isogenic, engineered “models” of tumorigenesis revealed
several electrophilic compounds with modest selectivity for
fully transformed cells over isogenic immortalized cells. These
observations stress the need for caution in interpreting
correlations between ROS-elevating manipulations and cell
death but also suggest novel combination strategies and a
deeper investigation of electrophilic small molecules as
potential cancer-selective agents.
■ METHODS
Cell Culture. U2OS, EJ (T24), H1703, and HeLa were acquired
from ATCC and cultured in recommended media. HEC108 were
obtained from the Broad Institute/Novartis Cancer Cell Line
Encyclopedia and cultured in EMEM + 15% FBS. HMEL, SALE,
and SALER were a gift of Dr. Jesse Boehm, Broad Institute Cancer
Program. HMELR cells were generated (by addition of activated H-
RAS) and donated by Dr. Yashaswi Shrestha (Broad Institute Cancer
Program). BJhTERT and BJeLR were a gift of Prof. Brent Stockwell,
Columbia University, and were cultured in 4:1 DMEM/M199 + 15%
FBS. The isogenicity of these three models of tumorigenesis was
conﬁrmed using STR proﬁling (Molecular Diagnostics Laboratory,
Dana Farber Cancer Institute).
ROS Assays. CM-H2DCF-DA. Cells were plated at 5,000 per well
of 384-well black plates (Corning 3712) and allowed to recover
overnight. The next day (ca. 90% conﬂuence), dilutions of compounds
in DMSO were added by pin transfer (CyBio Vario, 100 nL per well).
Cells were incubated for 1 h. (For experiments measuring ROS at 8 h,
4,000 cells were plated; for 24 h measurements, 3,000 cells were
plated.) Media was then removed and replaced using a Combi liquid
handler with colorless DMEM (no supplements) containing CM-
H2DCF-DA and Hoechst 33342 as described previously.
23 During
high-throughput screening, light ﬁxation using 0.5% paraformaldehyde
was performed for 5 min prior to two additional washes with PBS and
a FLiPR plate reader was used. Intensity values were normalized on a
per-plate basis using the Genedata software package. During
subsequent studies, images were obtained using an IX_Micro
automated ﬂuorescence microscope (Molecular Devices). Quantita-
tion of pixel intensity was performed using MetaXpress software and
signal intensity was calculated relative to wells in the same plate treated
with DMSO. Dihydroethidium: The assay was performed as above
except for use of DHE at 10 μM instead of CM-H2DCF-DA.
Viability Assays. CellTiter-Glo. Cells were generally plated at
1,000 per well in white 384-well plates and allowed to attach overnight.
BJhTERT and BJELR were plated at 500 per well, and HMEL and
HMELR were plated at 750 per well, due to rapid growth kinetics.
HEC108 cells were chosen for measurement of viability after 5 days of
treatment on the basis of their slower growth kinetics and were plated
at 500 cells/well. After addition of compounds by pin transfer, plates
were incubated for 48 h (H1703, 72 h). At that time, media was
removed and replaced with a solution of CellTiter-Glo reagent in PBS.
Luminescence was read using an EnVision multimode plate reader,
and signal intensity was calculated relative to in-plate DMSO control
wells. For co-treatment with antioxidants and other compounds (e.g.,
BSO), after overnight recovery the culture media was removed and
replaced with fresh media containing the desired antioxidant or other
agent. After 1 h, test compounds were added by pin transfer and the
assay proceeded as above.
GSH/GSSG Glo Assay. Cells were plated at 1,000 per well in white
384-well plates and allowed to attach overnight. After addition of
compounds by pin transfer, plates were incubated for 6 h. At that time,
media was removed and cells were washed with PBS. Total glutathione
was then measured according to manufacturer’s instructions
(Promega) with measurement of luminescence performed using an
EnVision multimode plate reader.
ARE-Luciferase Assays. IMR32 cells were plated at 10,000 per
well in white 384-well plates and assayed using Bright-Glo (Promega)
as previously described.
24
Source of Chemicals. Screening hits were obtained from the
Broad Institute Chemical Biology Platform and were assessed for
purity by LC−MS analysis. BRD9092 and BRD56491 were addition-
ally purchased from ChemDiv, and BRD5459 was purchased from
Sigma. These repurchased supplies provided equivalent activity in all
assays. Erastin, BSO, vitamin E (α-tocopherol), and N-acetyl cysteine
were purchased from Sigma; PX12 was purchased from Tocris.
BRD1378 was resynthesized and puriﬁed by HPLC and showed
comparable activity to supplies provided by Broad CB Platform.
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Figure 5. ROS-enhancing chemical probes frequently create a more
oxidizing cell state without overt toxicity to cancer cell lines.
Glutathione synthesis can be a dependency of cells treated with
such probes, as co-treatment with the glutathione synthesis inhibitor
BSO often leads to potent cell death.
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